| Literature DB >> 24427500 |
Hassan Abolhassani1, Amir Salek Farrokhi2, Shabnam Pourhamdi1, Payam Mohammadinejad1, Bamdad Sadeghi1, Seyed-Mohammad Moazzeni2, Asghar Aghamohammadi1.
Abstract
OBJECTIVE: Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by reduced serum level of IgG, IgA or IgM and recurrent bacterial infections. Class switch recombination (CSR) as a critical process in immunoglobulin production is defective in a group of CVID patients. Activation-induced cytidine deaminase (AID) protein is an important molecule involving CSR process. The aim of this study was to investigate the AID gene mRNA production in a group of CVID patients indicating possible role of this molecule in this disorder.Entities:
Keywords: AICDA Protein; Activation-Induced Cytidine Deaminase; Class Switching; Common Variable Immunodeficiency
Year: 2013 PMID: 24427500 PMCID: PMC3883376
Source DB: PubMed Journal: Iran J Pediatr ISSN: 2008-2142 Impact factor: 0.364
Primer sequences for β–actin and AID genes
| Gene | Primer sequence |
|---|---|
|
| Forward: 5‘-TACCACTGGCATCGTGATGGACT-3‘ |
| Reverse: 5‘-TCCTTCTGCATCCTGTCGGCAAT-3‘ | |
|
| Forward: 5‘-GAGGCAAGAAGACACTCTGG-3‘ |
| Reverse: 5‘-GTGACATTCCTGGAAGTTGC-3‘ |
Aid: Activation-induced cytidine deaminase
Fig. 1Electrophoresis of AID gene RT-PCR products (749 base pairs). PBMCs of both patient and controls were studied for mRNA expression after being simulated by CD40L and IL-4. A-D (patients) and E-G (control) samples show normal expression of mRNA
Fig. 2Electrophoresis of β-actin gene RT-PCR products (510 base pairs). β–actin gene was used as an internal control to evaluate the synthesis and production of cDNA. A and B are patients’ samples while C, D and E are samples from the control groups
Demographic and immunologic data comparing between three groups of Common variable immunodeficiency cases classified based on activation-induced cytidine deaminase mRNA expression
| Parameters | Reduced AID mRNA G1 (N = 4) Mean (SD) | Normal AID mRNA (N = 20) Mean (SD) | Increased AID mRNA G2 (N = 5) Mean (SD) |
| |||
|---|---|---|---|---|---|---|---|
| total | G1 and G2 | G1 and Normal group | G2 and Normal group | ||||
|
| 3.0 (2.82) | 3.38 (0.44) | 2.7 (0.41) | 0.3 | 1 | 0.9 | 0.9 |
|
| 6.25 (3.0) | 9.26 (1.1) | 6.6 (0.92) | 0.7 | 1 | 0.6 | 0.8 |
|
| 3.2 (2.6) | 5.8 (0.7) | 3.8 (0.53) | 0.5 | 1 | 0.5 | 0.7 |
|
| 11.0 (3.16) | 19.6 (10.3) | 16.4 (9.09) | 0.2 | 0.8 | 0.1 | 0.7 |
|
| 9900.0 (1979.8) | 7526.6 (4534.4) | 5152.0 (4195.7) | 0.3 | 0.4 | 0.3 | 0.4 |
|
| 4550.9 (1202.1) | 2920.45 (1507.9) | 2268.8 (1385.0) | 0.6 | 1 | 1 | 0.7 |
|
| 3731.5 (2372.8) | 1927.07 (1233.4) | 1270.8 (476.1) | 0.1 | 0.06 | 0.1 | 0.5 |
|
| 2053.9 (1480.0) | 1139.2 (452.7) | 680.4 (557.2) | 1 | 0.2 | 0.3 | 0.5 |
|
| 1417.2 (899.2) | 751.5 (372.1) | 577.0 (238.5) | 0.9 | 0.4 | 0.7 | 0.8 |
|
| 396.8 (98.1) | 403.2 (146.7) | 520.7 (144.2) | 0.4 | 0.02 | 0.5 | 0.07 |
|
| 7.6 (3.0) | 13.5 (4.9) | 10.9 (2.4) | 0.6 | 0.6 | 0.3 | 0.7 |
|
| 14.2 (10.4) | 11.4 (9.1) | 5.9 (1.8) | 0.3 | 0.4 | 0.8 | 0.2 |
|
| 189.3 (38.6) | 321.5 (256.6) | 245.7 (200.9) | 0.5 | 0.9 | 0.4 | 0.8 |
|
| 8.5 (6.3) | 9.0 (4.2) | 19.42 (3.1) | 0.5 | 0.01 | 0.5 | 0.04 |
|
| 23.0 (12.7) | 41.3 (22.2) | 43.2 (14.9) | 0.5 | 0.6 | 0.3 | 1 |
|
| 1.09 (0. 42) | 4.02 (0.53) | 6.47 (3.0) | 0.2 | 0.02 | 0.04 | 0.4 |
|
| 0.60 (0.31) | 3.97 (0.53) | 6.4 (5.7) | 0.2 | 0.01 | 0.02 | 0.08 |
P-value of ANOVA test;
P. value of Post Hoc analysis